How gefitinib affects cancer cells with different EGFR mutations
Author Information
Author(s): Pedersen M W, Pedersen N, Ottesen L H, Poulsen H S
Primary Institution: Copenhagen University Hospital
Hypothesis
What is the effect of gefitinib on the phosphorylation and growth of cells expressing normal EGFR and the mutant EGFRvIII?
Conclusion
Gefitinib inhibits normal EGFR but has a complex and less effective impact on cells expressing the mutant EGFRvIII, sometimes even promoting their growth.
Supporting Evidence
- Gefitinib effectively inhibits phosphorylation of EGFR in cells expressing normal levels.
- Cells expressing the mutant EGFRvIII require higher concentrations of gefitinib for effective inhibition.
- Low concentrations of gefitinib can stimulate proliferation in EGFRvIII-expressing cells.
Takeaway
This study looks at how a cancer drug called gefitinib works on different types of cancer cells. It found that while it can stop some cancer cells from growing, it can actually help others grow more.
Methodology
The study used various cell lines to analyze the effects of gefitinib on EGFR and EGFRvIII phosphorylation and signaling.
Limitations
The study primarily used in vitro models, which may not fully replicate in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website